Provided by Tiger Fintech (Singapore) Pte. Ltd.

Tango Therapeutics Inc.

1.95
+0.0000
Volume:405.24K
Turnover:791.38K
Market Cap:210.81M
PE:-1.63
High:2.04
Open:1.95
Low:1.92
Close:1.95
Loading ...

Tango Therapeutics Inc : Leerink Partners Cuts Target Price to $10 From $19

THOMSON REUTERS
·
07 Nov 2024

Wedbush Adjusts Tango Therapeutics Price Target to $9 From $13, Maintains Outperform Rating

MT Newswires Live
·
07 Nov 2024

Tango Therapeutics Inc : Piper Sandler Cuts Target Price to $15 From $18

THOMSON REUTERS
·
06 Nov 2024

Tango Shares Plunge After 3Q Loss, Product Plans

Dow Jones
·
06 Nov 2024

Wall Street Cheers Trump Election Win as US Equity Futures Rise Pre-Bell

MT Newswires Live
·
06 Nov 2024

BRIEF-Tango Therapeutics Q3 Basic EPS USD -0.27

Reuters
·
06 Nov 2024

Tango Therapeutics Q3 Net Income USD -29.167 Million VS. Ibes Estimate USD -37.8 Million

THOMSON REUTERS
·
06 Nov 2024

Press Release: Tango Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights

Dow Jones
·
06 Nov 2024

BRIEF-Tango Therapeutics Reports Positive TNG462 Clinical Data And Provides Update On PRMT5 Development Program

Reuters
·
06 Nov 2024

Tango Therapeutics Inc: Multiple Tng462 Combination Studies Planned in 1H 2025

THOMSON REUTERS
·
06 Nov 2024

Tango Therapeutics Inc: Tng462 Demonstrated Durable Clinical Activity Across Multiple Tumor Types

THOMSON REUTERS
·
06 Nov 2024

Tango Therapeutics Reports Positive Tng462 Clinical Data and Provides Update on Prmt5 Development Program

THOMSON REUTERS
·
06 Nov 2024

Tango Therapeutics Inc: Tng908 Enrollment Being Stopped to Fully Resource Tng462 and Tng456

THOMSON REUTERS
·
06 Nov 2024

Tango Therapeutics Reports Positive TNG462 Clinical Data and Provides Update on PRMT5 Development Program

Business Wire
·
06 Nov 2024

Tango Therapeutics Price Target Maintained With a $13.00/Share by HC Wainwright & Co.

Dow Jones
·
28 Oct 2024

Tango Therapeutics Repeat Insider Selling Not A Positive Indicator

Simply Wall St.
·
06 Oct 2024